RedHill Biopharma (RDHL) Posts Smaller Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
June 23, 2022 7:00 AM EDTTargeting positive cash from operations to start during H2/22[1]
Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months
Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21
Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022
Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21... More
